Budesonide
What is it: An inhaled synthetic steroid to curb persistent respiratory inflammation.AKA: Entocort, Pulmicort, Rhinocort, Uceris- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
12 Research papers
Referenced in this guide
21 Patient views
Contributed in this guide
Figure out what Budesonide means for you
Page contents
Basics: What you need to know
Budesonide is a synthetic, non-halogenated corticosteroid formulated to address inflammation in a targeted manner. In its inhaled form, it has been considered for the long-term management of persistent respiratory challenges following viral infection. By reducing airway inflammation and inhibiting the overproduction of inflammatory molecules, it can help those experiencing lingering breathing difficulties. This specialized approach aims to help stabilize immune responses in the respiratory tract, potentially easing symptoms and improving overall lung function.
History and development
- Swedish roots: First patented in 1973 by Astra (a Swedish pharmaceutical company), budesonide emerged as a more targeted alternative to older corticosteroids.
- Refined inhalation focus: Researchers concentrated on inhalable forms in the late 1970s and early 1980s to improve local impact on airways and reduce systemic side effects.
- Multiple brand variants: Over time, distinct formulations like Pulmicort, Rhinocort, Entocort, and Uceris were developed to specifically address asthma, allergic rhinitis, Crohn’s disease, and ulcerative colitis.
- Key developments: Innovations in particle size and inhaler design further enhanced budesonide’s capacity to deliver high concentrations directly to inflamed tissues.
What is known
- Targeted inflammation control: Inhaled budesonide helps reduce inflammatory signals in the airways, alleviating chronic cough and breathing difficulties.
- Well-documented safety: Long-standing clinical use shows lower rates of systemic steroid complications due to its limited absorption in the bloodstream.
- Lesser-known perks: Some patients report improved sense of smell and fewer congestion episodes, likely because of budesonide’s local impact on sinus and nasal pathways.
- Secondary anti-inflammatory effects: It may moderate immune overactivity, contributing to an overall reduction in airway hyperresponsiveness.
- Potential risk triggers: If misused or overused, it can provoke oral thrush or other steroid-related changes in the throat, underscoring the need for rinsing the mouth after use.
What is not known
- Optimal dosing for post-viral care: Although widely prescribed, the most effective dose and duration specifically for lingering post-viral symptoms remain undetermined.
- Long-term outcomes: There is limited data on how extended inhaled budesonide therapy affects complex, multi-system conditions over many months.
- Broader symptom relief: While it can help with respiratory issues, its effect on non-respiratory symptoms (such as brain fog or fatigue) is still unclear.
- Mechanistic specifics: The precise ways budesonide’s local and systemic influences alter the course of recurrent inflammation need further investigation.
- Individual variability: Different patient backgrounds and comorbidities lead to varied responses, emphasizing the need for personalized treatment strategies.
- Local targeting: Budesonide binds to airway tissues, reducing cytokine release that fuels inflammation.
- Immune moderation: It tempers overactive immune responses in the respiratory tract, thereby lessening flare-ups.
- Reduced airway reactivity: By calming inflamed cells, it can help alleviate chest tightness and frequent coughing.
- Precision delivery: Inhaled formulations ensure high concentrations reach problem areas with minimal systemic absorption.
- Consistent exposure: Protocol-based use maintains even levels of the medication for steady anti-inflammatory action.
- Oral thrush risk: Fungal overgrowth can occur in the mouth, requiring proper rinsing.
- Hoarseness or irritation: Throat discomfort sometimes emerges due to local steroid contact.
- Nasal dryness: When used in sinus passages, dryness or mild nosebleeds can happen.
- Possible systemic impact: Though minimal, high-dose or prolonged use may raise systemic steroid side effects.
- Allergy concerns: Rare individuals may develop reactions to inactive ingredients in the inhaler.
- Uncertainty in efficacy: Some experts argue evidence on the long-term benefits for post-viral respiratory issues is still emerging.
- Varying guidelines: Different clinical groups may recommend or discourage its routine use due to limited large-scale studies.
- Fears of immunosuppression: Critics worry that using any steroid agent over extended periods might hamper natural immune defenses.
- Balancing side effects: Some clinicians question whether the benefits outweigh potential adverse effects for mild or moderate cases of residual symptoms.
Patient views
Experiences
- Patients appreciate budesonide's ability to reduce shortness of breath and lung pain.
- Many find it helpful for managing inflammation in the lungs.
- Some report improved breathing and reduced chest tightness.
- It allows patients to perform daily activities like walking stairs or holding conversations.
Challenges
- Some patients experience no improvement after weeks of use.
- Nasal corticosteroids are ineffective for about half of users.
- Long-term use may cause dependency or immune system weakening.
- Side effects like nasal swelling or jitteriness are reported.
Tips
- Use a spacer for inhalers to improve effectiveness.
- Consult a doctor about proper dosage and particle type.
- Consider combining budesonide with breathing exercises.
- Monitor symptoms closely and adjust treatment as needed.
To calculate the reported effectiveness for a patient view, the model first analyses whether it can be ascertained that the person writing the review has had direct experience of the treatment for themselves or a loved one. If so, it then uses sentiment analysis to rate their view from 1-5 on how effective this treatment was for them, with 1 being the least effective, and 5 the most effective.
Patient view
This treatment unfortunately did not help me after 12 weeks of nebulizer treatments.
June 2024 • Turnto Consumer Review
Patient view
I have suffered from moderate/severe shortness of breath (among so many other things) since contracting Covid 19 in July ‘22. I have tried countless inhalers. The only treatment that has helped is a twice daily Symbicort inhaler combined with nebulized budesonide. The patient still struggles with SOB but it’s more manageable. The patient can hold a short conversation or walk a flight of stairs without getting out of breath! The patient also practices box breathing throughout the day. Now if only the patient could find an answer for the debilitating fatigue, dizziness and headaches…
June 2024 • Turnto Consumer Review
What and who it targets
Respiratory inflammation sufferers
Targets inflammation in airways effectively.
Fatigue with respiratory origin
Improves breathing, reducing fatigue.
Asthma-like symptoms
Manages airway constriction and inflammation.
Chronic cough patients
Reduces airway irritation and coughing.
Relevant research
How much evidence on this?
- Multiple studies explore corticosteroids for long COVID treatment.
- Research spans over 3 years, starting in 2020.
- Budesonide studied in systemic and inhaled forms.
- Moderate volume of studies, including case reports and trials.
Research focusing on
- Budesonide improves lung function in some long COVID cases.
- Side effects include risks like avascular necrosis.
- Recovery may involve pulmonary rehabilitation post-treatment.
- Researchers exploring immune modulation and long-term effects.
What needs more research?
- Long-term safety of budesonide for long COVID unclear.
- Optimal dosage and duration for treatment not established.
- Mechanisms of budesonide's effects on long COVID symptoms.
- Effectiveness across diverse patient populations.
- ⬤ Minimal research: Very little scientific study exists, with no or very few peer-reviewed studies. Insufficient data for conclusions.
- ⬤⬤ Limited research: Few studies exist, mostly small trials or case reports. Findings are preliminary and lack strong validation.
- ⬤⬤⬤ Moderately researched: Multiple studies, including mid-sized trials, exist. Some findings are replicated, but more research is needed.
- ⬤⬤⬤⬤ Well-researched: Supported by substantial evidence, including at least one large trial or meta-analysis.
- ⬤⬤⬤⬤⬤ Extensively studied: Numerous large studies and meta-analyses exist. Findings are widely accepted with strong scientific consensus.
Research
This paper reviewed 24 randomized controlled trials (RCTs) to evaluate the use of corticosteroids, including budesonide, for hospitalised COVID-19 patients. It focused on the dosage, method of administration, and clinical outcomes, aiming to understand their effectiveness in improving lung function and reducing mortality.
The review found that corticosteroids, including budesonide, improved lung function and reduced all-cause mortality in hospitalised COVID-19 patients. However, it highlighted the need for further studies to determine the best steroid regimen for treating long COVID symptoms.
For individuals with long COVID, this paper suggests that corticosteroids like budesonide might help manage persistent symptoms, but the optimal treatment approach is still unclear. It emphasizes the importance of further research to tailor treatments for long-term recovery.
This systematic review is reliable due to its inclusion of 24 RCTs and adherence to the PRISMA-ScR checklist. Published in a reputable journal, it provides a comprehensive analysis, though its focus on hospitalised patients may limit direct applicability to long COVID cases.
August 2024 • Pharmacy (Basel, Switzerland)
Research
This study explored the effects of a short course of corticosteroids, specifically prednisone, on patients experiencing persistent symptoms after recovering from COVID-19. Researchers conducted detailed immune profiling on nine patients with long-COVID symptoms and compared them to five individuals who had recovered from COVID-19 without lingering symptoms.
The study found that patients with long-COVID had immune system abnormalities, including increased inflammation and changes in immune cell populations. After a 4-day course of prednisone, these immune alterations were reversed, and the improvements were sustained for four months, correlating with a reduction in symptoms.
For individuals dealing with long-COVID, this research suggests that corticosteroids like prednisone might help alleviate symptoms by addressing underlying immune system issues. It provides hope for a potential treatment option that could improve quality of life for those affected.
This study is moderately reliable as it was published in a reputable journal, Biomedicines, and involved detailed immune profiling. However, the small sample size of nine patients limits the generalizability of the findings.
November 2021 • Biomedicines
Accessibility
- ⬤ Extremely Difficult to Access: Rare, experimental, or highly specialized. Requires multiple referrals, long wait times, travel, and strict follow-up.
- ⬤⬤ Difficult to Access: Limited to select centers with moderate barriers. Requires referral, potential travel, and wait times of weeks to months.
- ⬤⬤⬤ Moderately Accessible: Available in larger hospitals or clinics. Requires a basic referral, with moderate wait times and some coordination.
- ⬤⬤⬤⬤ Easy to Access: Widely available in most clinics. Minimal referral, short wait times, and simple preparation or follow-up.
- ⬤⬤⬤⬤⬤ Trivial to Access: Easily found in pharmacies or clinics. No referral needed, minimal wait, and straightforward access.
- ⬤ Up to $100
- ⬤⬤ Up to $500
- ⬤⬤⬤ Up to $2000
- ⬤⬤⬤⬤ Up to $10,000
- ⬤⬤⬤⬤⬤ More than $10,000
Method to access
- Obtain a prescription from a healthcare provider.
- Available at local pharmacies and online platforms.
- May require prior authorization for insurance coverage.
- At-home use is possible with inhalers or nebulizers.
Cost
- Inhalation suspension: $64–$200 for 60 mL.
- Oral delayed-release capsules: $77–$494 for 100 capsules.
- Extended-release tablets: $494 for 30 tablets.
- Rectal foam: $624 for 66.8 grams.
- Prices vary by region and pharmacy.
Insurance cover
- Commonly covered for approved conditions like asthma and Crohn's disease.
- Coverage for Long Covid may require prior authorization.
- Patients should verify coverage with their insurance provider.
Locations
- Mayo Clinic: Offers comprehensive care for Long Covid.
- UCLA Health: Provides specialized Long Covid treatment.
- Vanderbilt Adult Post-COVID Clinic: Focuses on Long Covid recovery.
- Long Covid Alliance: Directory of clinics specializing in Long Covid.
- Local pharmacies: Budesonide is widely available with a prescription.
Frequently asked questions
Explore other treatments
It's a lot of information, isn't it?
Turnto's personal AI Assistant can help you figure out what this all means for you
© 2026 Turnto
